AML-1 |
CCLG-2019 |
High risk |
PTPN11 |
KMT2A-MLLT3,
MLL-AF9 |
Chemotherapy + venetoclax |
Bone marrow no response |
- |
Died due to severe infection after chemotherapy |
AML-2 |
CCLG-2015 |
High risk |
GATA2, WT1 |
NUP98-HoxA9 |
Chemotherapy + transplantation |
9.36×10-3 |
2.609×10-3 |
Relapsed and
died 3 years after transplantation |
AML-3 |
CCLG-2019 |
High risk |
No |
No |
Chemotherapy + venetoclax +
transplantation |
4.67×10-2 |
7.72×10-2 |
Died after
transplantation |
AML-4 |
CCLG-2019 |
High risk |
No |
No |
Chemotherapy + venetoclax +
transplantation |
- |
Negative |
In transplantation |
AML-5 |
CCLG-2019 |
High risk |
IDH2, NRAS, WT1 |
No |
Chemotherapy + venetoclax + transplantation |
6×10-4 |
9×10-4 |
One year
after transplantation |
AML-6 |
CCLG-2019 |
Intermediate risk |
IDH1, NPM1, PTPN11 |
Low-level FLT3-ITD |
Chemotherapy + venetoclax + gilteritinib |
Negative |
Negative |
In chemotherapy |
AML-7 |
CCLG-2019 |
High risk |
No |
No |
Chemotherapy + venetoclax +
transplantation |
|
|
One year after transplantation |
AML-8 |
CCLG-2019 |
Standard risk |
No |
CBFβ-MYH11 |
Chemotherapy |
Negative |
Negative |
Drug withdrawal for three
years |
AML-9 |
CCLG-2019 |
High risk |
RUNX1, ASXL1, SETBP1, EZH2 |
No |
Chemotherapy + venetoclax + transplantation |
1.44×10^e-2 |
1.83×10^e-2 |
One year after transplantation |
AML-10 |
CCLG-2019 |
High risk |
No |
No |
Chemotherapy +
transplantation |
|
3.4×10-3 |
Two years after
transplantation |
AML-11 |
CCLG-2015 |
Standard risk |
PHF6 |
AML1-ETO |
Chemotherapy |
2.694×10-3 |
4.3×10-4 |
Drug withdrawal for five
years |
AML-12 |
CCLG-2015 |
Intermediate risk |
PTPN11 |
No |
Chemotherapy |
5.05×10-2 |
2.28×10-2 |
Gave up and died after
chemotherapy |
AML-13 |
CCLG-2015 |
High risk |
WT1 |
No |
Chemotherapy +
transplantation |
|
Positive |
Six years after
transplantation |
AML-14 |
CCLG-2015 |
Standard risk |
TP53 |
AML1-ETO |
Chemotherapy |
1.413×10-1 |
6.9×10-2 |
Drug withdrawal for six
years |
AML-15 |
CCLG-2015 |
High risk |
c-KIT,TP53 |
CBFβ-MYH11 |
Chemotherapy + transplantation |
2.43×10^-3 |
2.04×10-3 |
Six years
after transplantation |
APL-1 |
APL-2016 |
Standard risk |
No |
PML-RARA |
Chemotherapy |
Negative |
5.87×10-2 |
Drug withdrawal for three years |